Trump Secures Main Win as AstraZeneca Joins Pfizer in Decreasing US Drug Costs
President Donald Trump secured a significant victory Friday as AstraZeneca agreed to decrease its prescription drug costs for Medicaid—a transfer that follows the same deal made by Pfizer and marks a middle level within the administration’s push for extra reasonably priced drugs.
In accordance with AP, the settlement, made public throughout a White Home Oval Workplace occasion, commits AstraZeneca to “most–favored–nation” pricing for Medicaid.
Meaning the corporate will match the bottom drug costs provided in different rich nations.
Trump celebrated the deal, saying it may result in US costs being “the bottom worth anyplace on the planet.”
AstraZeneca CEO Pascal Soriot joined Trump for the announcement. With a wry tone, he later admitted that the negotiations had been intense: the president and his staff “actually saved me up at evening.”
Below the brand new deal, AstraZeneca can even assure the pricing commonplace for newly launched medication.
This transfer follows on the heels of Pfizer’s latest settlement with the administration. Each offers construct off an govt order Trump signed in Might: drugmakers got the choice to voluntarily cut back costs or face tighter limits on what the federal government pays.
BREAKING: Trump simply introduced that AstraZeneca, the biggest drug producer within the UK, might be investing $50 billion in the USA within the subsequent 5 years.
They can even promote their medication to People at favored nations pricing by means of “TrumpRX”
AMAZING! pic.twitter.com/g5gv76UWR7
— George (@BehizyTweets) October 10, 2025
Trump Touts AstraZeneca’s $4.5B Deal
Trump took a swipe at AstraZeneca’s preliminary resistance, quipping, “The tariffs have been a giant purpose he got here right here.”
The president additionally highlighted AstraZeneca’s dedication to broaden manufacturing within the US by asserting a brand new $4.5 billion manufacturing plant in Virginia, which is simply a part of a $50 billion funding plan by means of 2030.
That facility alone is predicted to create round 3,600 US jobs.
AstraZeneca, primarily based in Cambridge, UK, produces remedies comparable to Tagrisso for lung most cancers, Lynparza for ovarian most cancers, and Calquence for leukemia—collectively producing greater than $7.5 billion in US gross sales final yr.
Whereas the bulletins have been met with reward by drug-cost advocates, some specialists warn that inserting all hope on the drugmakers may very well be dangerous with out stronger US insurance policies to again them up.
Questions stay over how a lot sufferers and states will really profit, on condition that Medicaid already secures a “greatest worth” deal and most sufferers do not pay full value out of pocket, CBS Information reported.
Trump additionally launched a brand new initiative: an internet site referred to as TrumpRx.gov, coming in January 2026.
Sufferers will be capable of order medicines immediately from Roche and AstraZeneca by means of the positioning at decreased money costs.
Initially revealed on vcpost.com
